Articles
5,948 Articles
Psychedelic Spotlight
/
Nov 29, 2023
New Study Says LSD and Psilocybin Could Outperform Opioids for Pain, Without Developing Tolerance
Classic psychedelics might effectively kill pain with even greater vigor over time, sharply contrasting with opioids.
Psilocybin
LSD
Psychedelic Invest
/
Nov 29, 2023
Wesana Health Announces Restructuring of Promissory Note Receivable
Wesana Health Holdings Inc. (CSE: WESA.X) (OTCQB: WSNAF) (the “Company“), announced the execution of a Confidential Settlement and Release Agreement (“Settlement Agreement”) between Wesana Health Clinics Corp. (“Wesana”), a subsidiary of the Company, and APS Innovations LLC. (the...
Zen Habits
/
Nov 29, 2023
Creating a Slower Holiday Season
By Leo Babauta We’re in the midst of the holiday season, and with that can come a lot of abundance: Busier schedules, holiday parties, travelMore eating, more drinking, more excessMore shopping, more spending, more financial stressIt’s a beautiful season, but it can be a lot! In this article,...
Psychedelic Invest
/
Nov 29, 2023
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development...
Psychedelic Invest
/
Nov 29, 2023
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of...
Psilocybin
Psychedelic Invest
/
Nov 29, 2023
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics,...
Psilocybin
Psychedelic Invest
/
Nov 29, 2023
Mydecine Announces Update Regarding the Special Access Program
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to...
Psilocybin
MDMA
Psychedelic Invest
/
Nov 29, 2023
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company“), is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. The Company is providing this statement as an update regarding its litigation with GBB Drink Lab,...
Reality Sandwich
/
Nov 29, 2023
Ego Death and the Resurrection of the Self
Ego death is a metamorphosis. A transcendence from the ordinary. A place where the self dissolves and a new perception of reality emerges. The dissolution of the ego unravels the threads of conditioned identity, unveiling a fresh canvas upon which to explore and redefine one’s existence. For many,...
Psychedelics Today
/
Nov 29, 2023
From Stress Relief to Better Sleep: How Wearables Can Improve Psychedelic Outcomes
Though psychedelics have been used for thousands of years, modern technology is beginning to teach us more – much more – about their effects on our minds and bodies. We caught up with Apollo Neuro co-founder and neuroscientist and board-certified psychiatrist, Dr. David Rabin, to learn more...
Psychedelics Today
/
Nov 29, 2023
Navigating Psychedelic Spiritual Emergencies
What happens when you or someone close to you discovers a new or latent spiritual awareness as part of a psychedelic experience? Emergence is not always an emergency – but it helps to be prepared. Join Joe Moore and Kyle Buller for reflections and practical insights around this complicated topic. ...
Psychedelic Invest
/
Nov 29, 2023
Beckley Retreats Launches Signature Program for Personal Discovery and Transformation
Beckley Retreats, a psilocybin retreats and holistic wellbeing company, announced today the launch of its Signature Program for Personal Discovery and Transformation, an 11-week curriculum of preparation and integration support to help guests achieve the most significant benefit from their six-day...
Psychedelics - Green Market Report
/
Nov 29, 2023
Red Light Holland Trims Year-Over-Year Losses on Revenue Increase
Canadian mushroom and psychedelics firm Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) reported another C$1.1 million loss for its latest fiscal quarter, which ended Sept. 30. That’s a 15% improvement from its C$1.3 million losses for the same period a year prior, while increasing...
Psilocybin Alpha
/
Nov 28, 2023
Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates
This Issue of the Bulletin primarily focuses on psychedelic drug development and business stories, with around 4,000 words of coverage and analysis. Featured content in this Issue: Elsewhere, we spoke to Booking.com to better understand a headline figure from its travel predictions study, which...
Psychedelics Today
/
Nov 28, 2023
PT464 – Bodywork, Somatic Literacy, and Understanding Trauma: The Mind and Body Connection
In this episode, Kyle interviews Bessel van der Kolk, MD: pioneer clinician, researcher, and educator on traumatic stress; Founder of the Trauma Research Foundation; Professor of Psychiatry at Boston University Medical School; Principal Investigator of the Boston site of MAPS’ MDMA-assisted...
Psychedelic Invest
/
Nov 28, 2023
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused...
Psychedelics
Psychedelic Invest
/
Nov 28, 2023
Filament Health Signs Non-Binding Term Sheet for Convertible Note in Connection with Planned Business Combination
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical–stage natural psychedelic drug development company, today announced that the Company has signed a non-binding term sheet (the “Term Sheet”) providing for up to US$14.4 million in...
Psychedelic Invest
/
Nov 28, 2023
Irwin Naturals Reports Q3 2023 Financial Results
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) reported its financial results for its third quarter of fiscal 2023, the period ended September 30, 2023, on www.sedar.com. Financial Highlights for Q3 2023 Q3 revenue was $19.1 million, down 13.4% from $22.0...
Ketamine
Psychedelics - Green Market Report
/
Nov 28, 2023
Irwin Still Losing Money Despite Diversification
Nutraceutical firm Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) is still struggling to achieve profitability, despite selling off underperforming ketamine clinics while still developing its international cannabis industry footprint, the company reported in its third-quarter financials....
Ketamine
Psychedelics Today
/
Nov 27, 2023
Psychedelica Europa: A Deep Dive Into the Latest Psychedelic Research, Regulations and Policy
Embark on a thoughtful exploration with us, where we’ll delve into the complex world of psychedelic research, regulations, and policies shaping Europe’s mental health landscape. The demand for breakthrough treatment options and a more progressive regulatory and policy landscape in Europe is...
Psychedelic Invest
/
Nov 27, 2023
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. (“Seyltx”), a privately owned...
DMT
Reality Sandwich
/
Nov 27, 2023
Exploring Cognitive Support in Ketamine Treatment Models
Clinical ketamine treatment has emerged as a transformative therapy, offering hope to those facing mental health challenges like depression and PTSD, as well as individuals coping with physical ailments such as chronic pain and migraines. In this evolving landscape, brave professionals have taken...
Ketamine
Psychedelics - Green Market Report
/
Nov 27, 2023
Seelos Therapeutics Ketamine Drug Joins Defense Department PTSD Trial
Clinical-stage biopharmaceutical company Seelos Therapeutics Inc. (Nasdaq: SEEL) entered into a Department of Defense-funded trial to evaluate treatments for post-traumatic stress disorder in military personnel. The trial, an adaptive platform study, is designed to test multiple treatments...
Ketamine
Psychedelics - Green Market Report
/
Nov 27, 2023
Beckley Waves Has Big Plans For 2024
Green Market Report had a chance to sit down with Rock Feilding-Mellen to discuss the recent capital raise by Beckley Waves. The company is focused on building its academy to help train therapists in psychedelic drug treatments. The company believes that when MDMA is approved for MAPS, there will...
MDMA
Psychedelic Spotlight
/
Nov 24, 2023
The Biggest Psychedelic News This Week: November 20th-24th
Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a "both and" approach to treating ADHD.
Psilocybin
Psilocybin Alpha
/
Nov 24, 2023
Pα+ Psychedelic Patent Analysis (October 2023)
Written by Psychedelic Alpha’s Noah Smith with support from Editor-at-Large and patent attorney Graham Pechenik of Calyx Law.Our monthly Psychedelic Patent Analysis provides headline figures regarding published psychedelic patent applications and grants, before diving into commentary on a select...
Psychedelics Today
/
Nov 24, 2023
PT463 – Bringing Intention, Ceremony, and Inner Healing Intelligence to Modern Medicine
In this episode, Joe interviews Dana Lerman, MD: a decade-long infectious disease consultant who has since been trained in psychedelic-assisted therapy, ecotherapy, and Internal Family Systems, and is the Co-Founder of Skylight Psychedelics, where she prescribes IM ketamine and trains therapists who...
DoubleBlind Mag
/
Nov 23, 2023
2C-I Unveiled—From Research Chemical to Party Psychedelic
2C-B. DiPT. 4-AcO-DMT. When it comes to the names of novel psychedelic compounds, it sometimes feels like all that’s missing is an “H-I-J-K-L-M-N-O-P.” These new compounds are “research chemicals” or “designer drugs.” Their letter and number names represent the arrangement of atoms in...
LSD
DoubleBlind Mag
/
Nov 22, 2023
The 21st Century Witch Has Emerged from the Shadows and Into Our Consciousness
The rise of the witch archetype, both in modern culture (and in its initial incarnation as medieval-era paganism), coincides directly with eras rife with patriarchal suppression, religious extremism, and moral repression. As the cauldron of inequities boils, the witch mounts their broom and rides...
Vice
/
Nov 22, 2023
The Israelis and Palestinians Doing Ayahuasca Together
When Hamas militants went on a vicious rampage in early October and killed more than 1,200 people, Israel retaliated with overwhelming force. Gaza was pummelled with air strikes and invaded by land, with over 11,000 Palestinians killed. Despite the recent announcement of a four-day ceasefire, it is...
Ayahuasca
Psychedelic Spotlight
/
Nov 22, 2023
Stacking Psychedelic Microdoses with ADHD Medication? New Study Hints “Both And” Could Work
A new study exploring real-world psychedelic microdosing for ADHD could help reimagine the way we perceive and treat the condition.
Psychedelics Today
/
Nov 22, 2023
Explore Kanna: A Legal Psychoactive Plant Ally in Turbulent Times
Dive into the world of Kanna with two prominent leaders in the field of plant medicine, Joe Moore, Founder of Psychedelics Today, and Stephanie Wang, Founder and CEO of KA Empathogenics. In this live webinar they will unveil the extraordinary benefits of Kanna, shedding light on what it is, how to...
Psychedelics
Psychedelic Invest
/
Nov 21, 2023
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation...
Psychedelics - Green Market Report
/
Nov 21, 2023
Massachusetts Psychedelics Legislation Runs into Trouble
Campaign organizers in Massachusetts may have violated signature-gathering regulations and potentially invalidated thousands of signatures in their quest to legalize psychedelics in the state, according to nonprofit news organization WBUR. “We are working diligently to ensure we meet the...
MDMA
Psychedelics
Psychedelic Invest
/
Nov 21, 2023
Clearmind Medicine Announces 1-for-30 Reverse Share Split
Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to...
Psychedelic Invest
/
Nov 21, 2023
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage...
